South Korea Lowers Regulatory Barriers for Autologous Immune Cell Cancer Therapies
South Korean cancer patients will soon be able to receive autologous immune cell treatments domestically without undergoing lengthy preliminary clinical studies, following a government decision to streamline regulatory oversight in the biotechnology sector.
Autologous immune cell therapy involves extracting a patient’s immune cells from their blood, culturing them in a laboratory, and reinfusing them back into the patient to target cancer cells. Previously, these treatments fell under a medium-risk classification within South Korea’s advanced regenerative medicine framework. This designation mandated that medical institutions conduct preliminary clinical studies lasting two to three years before administering the therapies to patients.
South Korea lowers risk classification to curb overseas medical travel
The requirement for prolonged preliminary studies drove numerous South Korean cancer patients to seek out-of-country medical procedures, particularly in Japan. Japan classifies standard autologous immune cell culturing treatments as low-risk, allowing medical providers to offer them following review and notification processes without requiring prior clinical trials.
To curb this trend and expand domestic access, the South Korean government will lower the risk classification for specific autologous immune cell therapies that have demonstrated safety through existing domestic and international research data. Under the revised framework, institutions can bypass separate preliminary clinical studies. Instead, providers must submit existing safety research data and obtain approval for their treatment plans through the Advanced Regenerative and Bio Medical Deliberation Committee.
While South Korea already permits certain commercial anti-cancer drugs derived from a patient's own immune cells, those products require formal Ministry of Food and Drug Safety product approvals and operate independently of the advanced regenerative medicine treatment framework.
Government expands stem cell research and relaxes medical data rules
Alongside changes to immune cell therapies, the government announced plans to expand clinical research for stem cell treatments targeting knee osteoarthritis and chronic pain. The state will directly fund and oversee a two-year clinical research project involving 330 patients undergoing autologous stem cell culture treatments.
Data governance rules are also shifting. Institutional Review Board (IRB) reviews will no longer be mandatory for research utilizing medical information that has been pseudonymized so that researchers cannot identify individuals. Previously, even pseudonymized health data required IRB approval prior to use.
Additional Regulatory Overhauls for Autonomous Vehicles and Startups
The government package extends beyond biotechnology into autonomous driving and corporate startup regulations. Autonomous vehicles currently face operational limits restricting them to designated pilot testing zones. Under upcoming legislative amendments slated for December, driverless vehicles will be permitted to travel outside designated zones strictly for charging and garage transit.
What is the difference between immune cell drugs and regenerative therapies?
What is the difference between commercial immune cell drugs and advanced regenerative medicine therapies?
Commercial anti-cancer drugs manufactured from a patient’s immune cells require direct product approval from the Ministry of Food and Drug Safety. In contrast, advanced regenerative medicine treatments are hospital-administered procedures involving cell extraction, culturing, and reinfusion governed by specialized deliberation committees and clinical guidelines.
Which patients are targeted by the newly expanded stem cell clinical research?
The government-backed clinical research program focuses on patients suffering from knee osteoarthritis and chronic pain, involving 330 participants monitored over a two-year period for autologous stem cell culture treatments.
How will medical data research change under the new policy?
Researchers utilizing medical information that has been processed to completely prevent individual identification will no longer be required to undergo Institutional Review Board reviews before conducting their studies.